Desaymard C, Howard J G
Eur J Immunol. 1975 Aug;5(8):541-5. doi: 10.1002/eji.1830050807.
The immunogenicity and tolerogenicity of 2,4-dinitrophenyl (DNP) conjugates of levan, type 3 pneumococcal polysaccharide (SIII), dextran B512 and dextran B 1299 with different levels of substitution were assessed in vivo. It was confirmed that, as in vitro, conjugates with low epitope density are solely immunogenic for Bmu cells, whereas higher density conjugates are both immunogenic and tolerogenic according to dosage. The maximal anti-DNP plaque-forming cell responses attainable varied by 2 log10 according to the carrier, being greatest with dextrans and least with SIII. The effect of the carrier on immunogenicity was not attributable to B cells responding to it, as concurrent tolerization by either free polysaccharide or the conjugate itself was without effect. Optimal immunization was succeeded by varying degrees of responsiveness ("exhaustion") which was greatest with the more immunogenic conjugates. In contrast, reduction of tolerizing dose by cyclophosphamide suppression was only a feature of more highly substituted conjugates.
对不同取代水平的左聚糖、3型肺炎球菌多糖(SIII)、葡聚糖B512和葡聚糖B1299的2,4-二硝基苯基(DNP)缀合物的免疫原性和耐受性进行了体内评估。结果证实,与体外情况一样,低表位密度的缀合物对Bmu细胞仅具有免疫原性,而较高密度的缀合物根据剂量兼具免疫原性和耐受性。根据载体不同,可达到的最大抗DNP空斑形成细胞反应相差2个对数级,葡聚糖的反应最大,SIII的反应最小。载体对免疫原性的影响并非归因于对其产生反应的B细胞,因为游离多糖或缀合物本身同时诱导的耐受性均无效果。最佳免疫接种后会出现不同程度的反应性降低(“耗竭”),免疫原性更强的缀合物这种情况最明显。相比之下,通过环磷酰胺抑制来降低耐受剂量只是取代程度更高的缀合物的一个特征。